《大行》美银证券升康希诺(06185.HK)目标价至56元 重申“买入”评级

阿斯达克财经
Aug 22

美银证券发表报告指,康希诺(06185.HK) 上半年营收按年增长31%,净亏损收窄。 由于MCV4 Menhycia的销售增长,上半年来自脑膜炎球菌疫苗的收入按年增长38.4%。受惠于高利润疫苗销售额上升及产能利用率提升,上半年疫苗产品的毛利率提升至79.3%,按年上升12个百分点。

美银证券上调2028年至2034年每股盈利预测7%-11%,考虑到其在多种技术路线的领先研发能力及强劲的海外扩张能力,重申对康希诺“买入”评级,目标价由43元升至56元。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-21 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10